SG11201402144WA - Improved modulators of hec1 activity and methods therefor - Google Patents
Improved modulators of hec1 activity and methods thereforInfo
- Publication number
- SG11201402144WA SG11201402144WA SG11201402144WA SG11201402144WA SG11201402144WA SG 11201402144W A SG11201402144W A SG 11201402144WA SG 11201402144W A SG11201402144W A SG 11201402144WA SG 11201402144W A SG11201402144W A SG 11201402144WA SG 11201402144W A SG11201402144W A SG 11201402144WA
- Authority
- SG
- Singapore
- Prior art keywords
- methods therefor
- improved modulators
- hec1
- activity
- hec1 activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161564773P | 2011-11-29 | 2011-11-29 | |
PCT/US2012/067132 WO2013082324A1 (en) | 2011-11-29 | 2012-11-29 | Improved modulators of hec1 activity and methods therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201402144WA true SG11201402144WA (en) | 2014-09-26 |
Family
ID=48536070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201402144WA SG11201402144WA (en) | 2011-11-29 | 2012-11-29 | Improved modulators of hec1 activity and methods therefor |
Country Status (12)
Country | Link |
---|---|
US (2) | US8999983B2 (ja) |
EP (1) | EP2785714B1 (ja) |
JP (1) | JP5970554B2 (ja) |
KR (1) | KR101983585B1 (ja) |
CN (1) | CN104254534B (ja) |
AU (1) | AU2012345843B2 (ja) |
ES (1) | ES2712134T3 (ja) |
HK (1) | HK1202870A1 (ja) |
MX (1) | MX371378B (ja) |
SG (1) | SG11201402144WA (ja) |
TW (1) | TWI640519B (ja) |
WO (1) | WO2013082324A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11071736B2 (en) * | 2011-11-21 | 2021-07-27 | Taivex Therapeutics Corporation | Modulators of HEC1 activity and methods therefor |
CA2886895C (en) | 2012-10-02 | 2021-10-19 | Bayer Cropscience Ag | Heterocyclic compounds as pesticides |
AU2014347026A1 (en) * | 2013-11-06 | 2016-06-23 | Bristol-Myers Squibb Company | Substituted pyridine derivatives useful as GSK-3 inhibitors |
WO2015179312A1 (en) * | 2014-05-17 | 2015-11-26 | The Regents Of The University Of California | Centromere/kinetochore protein genes for cancer diagnosis, prognosis and treatment selection |
EP3758700A4 (en) | 2018-02-28 | 2021-11-17 | University of Southern California | COMPOSITIONS AND METHODS OF MODULATING INFLAMMATORY AND DEGENERATIVE DISORDERS |
TWI750905B (zh) * | 2020-11-19 | 2021-12-21 | 財團法人國家衛生研究院 | 噻唑化合物作為蛋白質激酶抑制劑 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0228175A (ja) * | 1987-12-14 | 1990-01-30 | Sawai Seiyaku Kk | チアゾール環およびテトラゾール環を有するカルボキシアミド誘導体およびその用途 |
AU5135998A (en) * | 1996-12-03 | 1998-06-29 | Banyu Pharmaceutical Co., Ltd. | Novel urea derivatives |
CA2380206A1 (en) * | 1999-07-26 | 2001-02-01 | Shionogi & Co., Ltd. | Pharmaceutical compositions exhibiting thrombopoietin receptor agonism |
CA2388508A1 (en) * | 1999-10-22 | 2001-05-03 | Takeda Chemical Industries, Ltd. | 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof |
EP1519736A2 (en) | 2002-06-12 | 2005-04-06 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of hec1 antagonists in the treatment of proliferative disorders and cancer |
WO2004033666A2 (en) | 2002-10-11 | 2004-04-22 | Board Of Regents, The University Of Texas System | Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases |
ZA200602755B (en) | 2003-09-06 | 2007-06-27 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
WO2005040135A1 (ja) * | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | 抗ストレス薬およびその医薬用途 |
TW200524575A (en) * | 2003-10-27 | 2005-08-01 | S Bio Pte Ltd | Biaryl linked hydroxamates: preparation and pharmaceutical applications |
CN1938279B (zh) * | 2004-01-30 | 2011-09-14 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白调控剂 |
WO2006136823A1 (en) * | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
WO2007004038A1 (en) | 2005-07-05 | 2007-01-11 | Pfizer Products Inc. | Aminothiazole derivatives as agonists of the thrombopoietin receptor |
WO2007008541A2 (en) * | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
SI1945632T1 (sl) * | 2005-11-08 | 2014-03-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto |
CA2633569A1 (en) * | 2005-12-12 | 2007-06-21 | Genelabs Technologies, Inc. | N-(5-membered heteroaromatic ring)-amido anti-viral compounds |
WO2007131071A2 (en) | 2006-05-02 | 2007-11-15 | Washington State University | Mig-7 as a specific anticancer target |
US20090181952A1 (en) * | 2008-01-14 | 2009-07-16 | Wyeth | Compounds useful as alpha7 nicotinic acetylcholine receptor agonists |
US20120108614A1 (en) * | 2008-05-14 | 2012-05-03 | Chong Jayhong A | Compounds and compositions for treating chemical warfare agent-induced injuries |
WO2009144548A1 (en) * | 2008-05-28 | 2009-12-03 | Glenmark Pharmaceuticals S.A. | Imidazo [2,1-b] purine derivatives as trpa1 modulators |
US20120046305A1 (en) * | 2008-09-24 | 2012-02-23 | Moran Magdalene M | Methods and compositions for treating respiratory disorders |
US8324385B2 (en) | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
DK2411397T3 (da) * | 2009-03-23 | 2013-08-05 | Glenmark Pharmaceuticals Sa | Isothiazol-pyrimidindionderivater som modulatorer af TRPA1 |
DE102009014484A1 (de) * | 2009-03-23 | 2010-09-30 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
EP2309273B1 (en) | 2009-09-16 | 2016-05-18 | ZEILLINGER, Robert | Novel tumor marker determination |
BR112012023355A2 (pt) * | 2010-03-17 | 2016-05-31 | Taivex Therapeutics Inc | composto, composição farmacêutica e método de ruptura da interação nek2/hec1 |
WO2013078145A1 (en) * | 2011-11-21 | 2013-05-30 | Taivex Therapeutics Corporation | Biomarkers for cancers responsive to modulators of hec1 activity |
-
2012
- 2012-11-28 TW TW101144601A patent/TWI640519B/zh active
- 2012-11-29 CN CN201280068425.5A patent/CN104254534B/zh active Active
- 2012-11-29 WO PCT/US2012/067132 patent/WO2013082324A1/en active Application Filing
- 2012-11-29 JP JP2014544894A patent/JP5970554B2/ja active Active
- 2012-11-29 MX MX2014006157A patent/MX371378B/es active IP Right Grant
- 2012-11-29 EP EP12853202.5A patent/EP2785714B1/en active Active
- 2012-11-29 AU AU2012345843A patent/AU2012345843B2/en active Active
- 2012-11-29 KR KR1020147017912A patent/KR101983585B1/ko active IP Right Grant
- 2012-11-29 ES ES12853202T patent/ES2712134T3/es active Active
- 2012-11-29 SG SG11201402144WA patent/SG11201402144WA/en unknown
- 2012-11-29 US US13/689,590 patent/US8999983B2/en active Active
-
2015
- 2015-03-11 US US14/645,292 patent/US10588909B2/en active Active
- 2015-04-22 HK HK15103447.6A patent/HK1202870A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2785714A4 (en) | 2015-09-09 |
HK1202870A1 (en) | 2015-10-09 |
ES2712134T3 (es) | 2019-05-09 |
AU2012345843A1 (en) | 2014-05-29 |
JP5970554B2 (ja) | 2016-08-17 |
TWI640519B (zh) | 2018-11-11 |
CN104254534A (zh) | 2014-12-31 |
TW201326164A (zh) | 2013-07-01 |
NZ624552A (en) | 2015-06-26 |
US10588909B2 (en) | 2020-03-17 |
EP2785714A1 (en) | 2014-10-08 |
US8999983B2 (en) | 2015-04-07 |
US20150250794A1 (en) | 2015-09-10 |
JP2014534271A (ja) | 2014-12-18 |
EP2785714B1 (en) | 2018-11-21 |
KR101983585B1 (ko) | 2019-05-29 |
MX2014006157A (es) | 2015-04-08 |
AU2012345843B2 (en) | 2017-11-23 |
WO2013082324A1 (en) | 2013-06-06 |
CN104254534B (zh) | 2017-07-14 |
US20130190312A1 (en) | 2013-07-25 |
MX371378B (es) | 2020-01-28 |
KR20140138596A (ko) | 2014-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL263020A (en) | New modulators and methods of use | |
IL247595A0 (en) | New modulators and methods of use | |
HK1176055A1 (zh) | 活動的調製器及其調製方法 | |
HK1215284A1 (zh) | 位點特異性酶和使用方法 | |
GB2488674B (en) | Catalyst and method of preparation | |
EP2672820A4 (en) | MANNOSID COMPOUNDS AND METHOD OF USE THEREOF | |
IL227333A0 (en) | A method for preparing lycosphingolipids and their uses | |
SG10201601792UA (en) | Novel modulators and methods of use | |
ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
SG10201506782XA (en) | Notum protein modulators and methods of use | |
EP2665486A4 (en) | COMPOSITIONS AND METHODS OF MODULATING ACTIVITY OF GAMMA-C CYTOKINES | |
HK1202870A1 (en) | Improved modulators of hec1 activity and methods therefor hec1 | |
EP2852397A4 (en) | HUWENTOXIN IV VARIANTS AND METHODS OF USE | |
EP2726218A4 (en) | ADHESIVE COMPLEX COACERVATES AND METHODS OF MAKING AND USING SAME | |
EP2763962A4 (en) | METHOD FOR TREATMENT WITH SIRT2 MODULATORS | |
EP2709999A4 (en) | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | |
EP2670245A4 (en) | ALPHA-CÉTOHÉTÉROCYCLES AND METHODS OF MAKING AND USING THEM | |
EP2753359A4 (en) | SERPINF2 BINDEMOLEKÜLE AND METHOD FOR THEIR USE | |
AP2013007019A0 (en) | Gaming system and method of use | |
EP2782670A4 (en) | COPPER ZIRCONIUM CATALYST AND METHOD FOR ITS USE AND MANUFACTURE | |
EP2898044A4 (en) | SOLID HYDROGEL MEDIA AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
EP2691420A4 (en) | MODULATORS OF B2 PLEXINE ACTIVITY | |
GB2516380B (en) | Catalyst and method of preparation | |
GB201316230D0 (en) | Catalysts and methods of making and using catalysts | |
AU2011901049A0 (en) | Catalysts and Methods of Use |